search
Back to results

Understanding Hypoglycaemia After Bariatric Surgery (HYPOBAR1)

Primary Purpose

Bariatric Surgery

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Dietary Supplement: Glucose
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Bariatric Surgery focused on measuring Roux-en-Y gastric bypass (RYGB), Hypoglycaemia, Insulin, Glucose, Incretins, Stable isotope

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gastric bypass (RYGB) surgery performed ≥ 6 months ago
  • Confirmed postprandial hypoglycaemia (continuous glucose monitoring or plasma glucose), with at least 2 episodes of Whipple's triad (symptoms, capillary of interstitial glucose ≤3.1mmol/L, symptom resolution by carbohydrate intake) ≤3 months ago
  • Normal glucose control at recruitment and absence of (pre)diabetes before bariatric surgery
  • Capacity to give informed consent

Exclusion Criteria:

  • Fasting hypoglycaemia suggesting hyperinsulinism of different aetiology
  • Use of medication that influence glucose metabolism
  • Bariatric procedures other than RYGB
  • Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Moderate to severe chronic kidney disease
  • Pregnancy or breastfeeding

Sites / Locations

  • Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

OGTT with 13C-labelled leucine

Arm Description

Intake of 75g of glucose with 1g of 13C leucine pre-feeding

Outcomes

Primary Outcome Measures

Fractional synthesis rate of de novo C-peptide synthesis (%/hr)
Calculated

Secondary Outcome Measures

C-peptide levels in blood
Measured
Insulin levels in blood
Measured
Glucagon levels in blood
Measured
Incretin levels in blood
Measured
Insulin sensitivity
Calculated
Beta cell responsivity
Calculated
Hepatic insulin extraction
Calculated
C-peptide levels in urine
Measured
C-peptide enrichment
calculated

Full Information

First Posted
July 25, 2018
Last Updated
December 3, 2018
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Erasmus Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03609632
Brief Title
Understanding Hypoglycaemia After Bariatric Surgery
Acronym
HYPOBAR1
Official Title
Exploring Beta Cell Function in Individuals With Postbariatric Postprandial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
September 20, 2018 (Actual)
Primary Completion Date
November 2, 2018 (Actual)
Study Completion Date
November 2, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Erasmus Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Postprandial hyperinsulinaemic hypoglycaemia is an increasingly recognized adverse side effect of bariatric surgery. Affected individuals experience low glucose levels 1-3 hours after intake of meals, accompanied by symptoms such as drowsiness, sweating, hunger and palpitations. Hypoglycaemia can be serious and have potential dangerous health impact (e.g. road accident or fall due to loss of consciousness). The pathophysiology is incompletely understood and more research is needed in search of preventive and therapeutic strategies.
Detailed Description
Obesity is a major global health concern that is associated with significant disability and mortality. Worldwide, the prevalence of obesity has doubled since 1980, affecting 13% of the global population. Bariatric surgery has been shown to be the most effective and durable treatment of severe obesity and leads to significant improvement of obesity-related comorbidity. However, postprandial hyperinsulinaemic hypoglycaemia (PHH) after bariatric surgery is a metabolic complication that is increasingly being recognized. Prevalence rates of up to 72% have been reported. PHH may have serious implications for affected patients, including negative effects on morbidity, mortality as well as quality of life. The pathophysiology of PPH is incompletely understood and suggests decreased adaptation of beta cell function to increased insulin sensitivity. The latter has been postulated to be largely secondary due to external factors outside the beta cells as a result of anatomical and hormonal changes after Roux-en-Y gastric bypass (RYGB). However, the intrinsic mechanistic effects of altered beta-cell function after RYGB in vivo are unknown and more exploration could lead to a better understanding of PHH pathogenesis and help identify targets for possible interventions. Previous studies performed enhanced beta cell analysis by following insulin synthesis in real-time based on stable isotope labelling of C-peptide during an oral glucose tolerance test (OGTT) in cohorts with normal and diabetic glucose tolerance. Applying the same methodological approach, albeit in a different target population (PPH after bariatric surgery), the present study seeks to explore whether or not the insulin hypersecretion can be explained by an increase in insulin synthesis, and secondly, whether potentially increased insulin synthesis can be related to other glucoregulatory hormones and measures of insulin sensitivity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bariatric Surgery
Keywords
Roux-en-Y gastric bypass (RYGB), Hypoglycaemia, Insulin, Glucose, Incretins, Stable isotope

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
OGTT with 13C-labelled leucine
Arm Type
Experimental
Arm Description
Intake of 75g of glucose with 1g of 13C leucine pre-feeding
Intervention Type
Other
Intervention Name(s)
Dietary Supplement: Glucose
Intervention Description
Intake of 75g of glucose with 1g of 13C leucine pre-feeding
Primary Outcome Measure Information:
Title
Fractional synthesis rate of de novo C-peptide synthesis (%/hr)
Description
Calculated
Time Frame
4.5 hours
Secondary Outcome Measure Information:
Title
C-peptide levels in blood
Description
Measured
Time Frame
4.5 hours
Title
Insulin levels in blood
Description
Measured
Time Frame
4.5 hours
Title
Glucagon levels in blood
Description
Measured
Time Frame
4.5 hours
Title
Incretin levels in blood
Description
Measured
Time Frame
4.5 hours
Title
Insulin sensitivity
Description
Calculated
Time Frame
4.5 hours
Title
Beta cell responsivity
Description
Calculated
Time Frame
4.5 hours
Title
Hepatic insulin extraction
Description
Calculated
Time Frame
4.5 hours
Title
C-peptide levels in urine
Description
Measured
Time Frame
4.5 hours
Title
C-peptide enrichment
Description
calculated
Time Frame
4.5 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gastric bypass (RYGB) surgery performed ≥ 6 months ago Confirmed postprandial hypoglycaemia (continuous glucose monitoring or plasma glucose), with at least 2 episodes of Whipple's triad (symptoms, capillary of interstitial glucose ≤3.1mmol/L, symptom resolution by carbohydrate intake) ≤3 months ago Normal glucose control at recruitment and absence of (pre)diabetes before bariatric surgery Capacity to give informed consent Exclusion Criteria: Fasting hypoglycaemia suggesting hyperinsulinism of different aetiology Use of medication that influence glucose metabolism Bariatric procedures other than RYGB Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator Moderate to severe chronic kidney disease Pregnancy or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Stettler, MD
Organizational Affiliation
Inselspital, Bern University Hospital, University of Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Understanding Hypoglycaemia After Bariatric Surgery

We'll reach out to this number within 24 hrs